BMO Capital Markets reiterated its Outperform rating on Eli Lilly and Company (NYSE:LLY), setting a price target of $900 ...

Major players including AbbVie, GSK, Sanofi, and Eli Lilly recently bolstered their R&D pipelines with a wave of acquisitions ...

Vertex and Eli Lilly are revolutionizing non-opioid pain management with NaV1.8 advancements. See why I'm bullish about LLY ...

Distributors of construction materials and related equipment faced selling pressure on Monday after a report showed that U.S.

Learn about May 2025’s top biotech deals, featuring major collaborations in RNA interference technology, small molecules, and ...